When was Generation Bio founded?

Generation Bio was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Generation Bio located?

Generation Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Generation Bio have?

As of Mar 31, 2026, the latest employee count at Generation Bio is 45.

Is Generation Bio a funded company?

Generation Bio is a funded company, having raised a total of $236M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 04, 2018.

How much is Generation Bio worth?

The last known valuation of Generation Bio was $***** as of Dec 15, 2025.

When was the latest funding round of Generation Bio?

Generation Bio's latest funding was a $***** Series C round on Jan 10, 2020, with participation from 10 investors.

What is the annual revenue of Generation Bio?

Annual revenue of Generation Bio is $19.9M as on Dec 31, 2024.

Where does Generation Bio rank among its competitors?

Generation Bio ranks 12th amongst 789 active competitors, of which 271 are funded. It stands 8th in terms of total funding among its competitors.

Who are the top competitors of Generation Bio?

Generation Bio's top competitors include Moderna, BridgeBio and Spark Therapeutics. Among them, Generation Bio secured the most recent funding round in January, 2020.

Generation Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Generation Bio is an acquired company based in Cambridge (United States), founded in 2016 by Mark Angelino, Robert M Kotin and Phillip Samayoa. It operates as a Developer of gene therapies for rare liver and eye diseases. Generation Bio has raised $236M in funding from Fidelity Investments and T. Rowe Price, with last known valuation of $*****. The company has 789 active competitors, including 271 funded and 219 that have exited. Its top competitors include companies like Moderna, BridgeBio and Spark Therapeutics.

Company Details

Developer of gene therapies for rare liver and eye diseases. The company provides non-viral gene therapies for phenylketonuria, hemophilia A, Wilson disease, Leber congenital amaurosis, Stargardt disease, and others. The Gene Wave technology is used for optimal titration and can also be re-dosed by using closed-ended DNA for gene therapy development. The ceDNA is packaged in a lipid nanoparticle that dissolves into the cytoplasm of a cell and heads to the nucleus to produce proteins.

Website: generationbio.com
Social
Email ID: *****@generationbio.com, *****@generationbio.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2016

Location

Cambridge, United States

Stage

Acquired

Total Funding

$236M in 3 rounds

Latest Funding Round

Series C, Jan 10, 2020, $*****

Last Known Valuation

$***** as on Dec 15, 2025

Investors

Fidelity Investments & 10 more

Ranked

12^th among 789 active competitors

Annual Revenue

$19.9M as on Dec 31, 2024

Employee Count

45 as on Mar 31, 2026

Similar Companies

Moderna & 975 more

Exit Details

Acquired by XOMA Corporation (Dec 15, 2025)

View Generation Bio's full profile

Generation Bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Generation Bio Co. CIN: 1733294 , United States, Active	Oct 20, 2016	$19.9M (As on Dec 31, 2024)	-	-
GENERATION BIO CIN: 814301284 , United States, Active	Dec 31, 2015	-	116 (As on Dec 31, 2024)	-

Generation Bio got acquired by XOMA Corporation on Dec 15, 2025.

Click here to take a look at Generation Bio's acquisition in detail

Generation Bio has raised a total funding of $236M over 3 rounds. Its first funding round was on Jan 04, 2018. Its latest funding round was a Series C round on Jan 10, 2020 for $*****. 10 investors participated in its latest round. Generation Bio has 11 institutional investors.

Here is the list of recent funding rounds of Generation Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 10, 2020	5543943	Series C	8349597	3813363	5903486	1570612
Feb 27, 2018	5189183	Series B	4813342	8167376	3848192	Invus & 4 more
Jan 04, 2018	5760671	Series A	1373679	4509315	6023191	Atlas Venture

Access funding benchmarks and valuations. Sign up today!

View details of Generation Bio's funding rounds and investors

The founders of Generation Bio are Mark Angelino, Robert M Kotin and Phillip Samayoa. Geoff McDonough is the CEO of Generation Bio.

Here are the details of Generation Bio's key team members:

Mark Angelino: Co-Founder & COO of Generation Bio. They serve on the board of 1 company.
Robert M Kotin: Former Co-Founder of Generation Bio and founder of 1 other company.
Phillip Samayoa: Co-Founder of Generation Bio.
Geoff McDonough: CEO of Generation Bio.

View details of Generation Bio's Founder profiles and Board Members

Generation Bio's employee count trend

Generation Bio has 45 employees as of Mar 26. Here is Generation Bio's employee count trend over the years:

Uncover Generation Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Generation Bio include Moderna, BridgeBio and Spark Therapeutics. Here is the list of Top 10 competitors of Generation Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Flagship Pioneering & 30 others	81/100
2nd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	KKR, Viking Global Investors & 20 others	75/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Children's Hospital of Philadelphia ... & 6 others	75/100
4th	Exact Sciences 1995, Madison (United States), Public	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Kintsugi Ventures, Great Point Partners & 8 others	73/100
5th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	72/100
6th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Third Rock Ventures, Pfizer Venture Investments ... & 9 others	72/100
7th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Third Rock Ventures & 15 others	72/100
8th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	FPV Ventures, Playground Global & 19 others	72/100
9th	Insitro 2018, San Francisco (United States), Series C	Developer of an AI-enabled technology platform for the treatment of infectious disease	$643M	Andreessen Horowitz, Foresite Capital & 18 others	72/100
10th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Bellevue Healthcare Trust, Ridgeback Capital Management ... & 13 others	71/100
12th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	BB Biotech, Foresite Capital & 9 others	69/100